Helicobacter pylori Infection and Nonsteroidal Anti-inflammatory Drug Use: Eradication, Acid-Reducing Therapy, or Both?

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 8, 2012, Pages 831-836

  Leung Ki, En Ling ^a   Chan, Francis K L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; COST EFFECTIVENESS ANALYSIS; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; OSTEOARTHRITIS; PEPTIC ULCER; PEPTIC ULCER BLEEDING; SIGNAL TRANSDUCTION; STOMACH MUCOSA LESION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINES AS TOPIC; HELICOBACTER INFECTIONS; HUMANS; MALE; TREATMENT OUTCOME;

EID: 84864083465     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.04.010     Document Type: Article

References (33)

1. Malfertheiner P., Chan F.K.L., McColl K.E.L. Peptic ulcer disease. Lancet 2009, 374:1449-1461.
2. Lanza F.L., Chan F.K., Quigley E.M., et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
3. Chan F.K. NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf 2005, 28:287-300.
4. Venerito M., Malfertheiner P. Interaction of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in gastric and duodenal ulcers. Helicobacter 2010, 15:239-250.
5. Lanas A. Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. Expert Opin Drug Saf 2011, 10:45-54.
6. Leung Ki E., Chan F.K.L. Interaction of H. pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol 2012, 26:163-172.
7. Huang J.Q., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002, 359:14-22.
8. Leontiadis G.I., Sreedharan A., Dorward S., et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007, 11:1-164.
9. Vergara M., Catalan M., Gisbert J.P., et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment Pharmacol Ther 2005, 21:1411-1418.
10. Hawkey C.J., Tulassay Z., Szczepanski L., et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998, 352:1016-1021.
11. Chan F.K., Sung J.J., Chung S.C., et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997, 350:975-979.
12. Labenz J., Blum A.L., Bolten W.W., et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002, 51:329-335.
13. Chan F.K., To K.F., Wu J.C., et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002, 359:9-13.
14. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001, 344:967-973.
15. Lai K.C., Lau C.S., Ip W.Y., et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003, 17:799-805.
16. Bianchi Porro G., Parente F., Imbesi V., et al. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users: response to omeprazole dual therapy. Gut 1996, 59:22-26.
17. Pilotto A., Di Mario F., Franceschi M., et al. Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects. Aliment Pharmacol Ther 2000, 14:1077-1082.
18. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991, 114:257-263.
19. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991, 115:787-796.
20. Fletcher E.H., Johnston D.E., Fisher C.R., et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther 2010, 32:831-839.
21. Lanas A., Fuentes J., Benito R., et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002, 16:779-786.
22. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002, 346:2033-2038.
23. Chan F.K.L., Ching J., Suen B.Y., et al. Effect of H. pylori eradication on the long-term incidence of recurrent ulcer bleeding in high-risk aspirin users: a 10-year prospective cohort study. Gastroenterology 2011, 140:S173-S174. (abstr).
24. Scheiman J.M., Bandekar R.R., Chernew M.E., et al. Helicobacter pylori screening for individuals requiring chronic NSAID therapy: a decision analysis. Aliment Pharmacol Ther 2001, 15:63-71.
25. Earnshaw S.R., Scheiman J., Fendrick A.M., et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011, 171:218-225.
26. FDA drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs) US Food and Drug Administration, Accessed: February 8, 2012. http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm.
27. Khalili H., Huang E.S., Jacobson B.C., et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012, 344:e372.
28. Abrahamsen B., Eiken P., Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011, 171:998-1004.
29. Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917.
30. Hagiwara T., Mukaisho K., Nakayama T., et al. Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori. Gut 2011, 60:624-630.
31. Malfertheiner P., Megraud F., O'Morain C., et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report. Gut 2007, 56:772-781.
32. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008, 103:2890-2907.
33. Cherubino P., Sarzi-Puttini P., Zuccaro S.M., et al. The management of chronic pain in important patient subgroups. Clin Drug Invest 2012, 32:35-44.